Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole
A Randomized, Controlled Trial of Adding Intravenous Pantoprazole to Conventional Treatment for the Immediate Relief of Dyspeptic Pain
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Bangkok
-
Patumwan, Bangkok, Thailand, 11130
- Emergency Medicine Unit, King Chulalongkorn Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- clinical diagnosis of acid-related dyspepsia
- age 15 to 50 years
Exclusion Criteria:
- pre-treatment 100-millimeter linear Visual Analog Scale (100-mm VAS) pain scores less than 5.0
- known cases of malignancies or terminal illnesses
- known cases of major medical problems
- allergic to studied drugs
- contraindicated to hyoscine butylbromide (glaucoma, myasthenia gravis, paralytic ileus, pyloric stenosis, prostatic enlargement, porphyria)
- received acid antisecretory agents (proton pump inhibitors or histamine-2 receptor antagonists), antispasmodic agents, alcoholic consumption, nonsteroidal anti-inflammatory drugs, aspirin and steroids within 5 days or oral antacids within 4 hours prior to the visit
- receiving clopidogrel, statins, iron therapies, warfarins, antiretroviral agents, which may have serious drug interaction with the proton pump inhibitors
- receiving drugs that have strong anticholinergic activities (e.g. acetylcholinesterase inhibitors for Parkinson's or Alzheimer diseases, antihistamines, antispasmodic agents, antipsychotics, skeletal muscle relaxants, tricyclic antidepressants) or decongestants, which may have serious drug interaction with hyoscine butylbromide
- suspected other alternative diagnoses (e.g. gut obstruction, biliary colic, pancreatitis, hepatitis or localized hepatobiliary infections, etc.)
- pregnancy or breast-feeding participants
- did not comprehend the Visual Analog Scale (VAS) evaluation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Conventional
Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline
|
10 ml of 0.9% sodium chloride solution
30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)
Other Names:
20 mg of intravenous hyoscine butylbromide
Other Names:
|
|
EXPERIMENTAL: Pantoprazole
Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole
|
30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)
Other Names:
20 mg of intravenous hyoscine butylbromide
Other Names:
80 mg of intravenous pantoprazole
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Scores on the 100-millimeter Visual Analog Scale (VAS) at 1 Hour After Treatment
Time Frame: 1 hour after treatment
|
Post-treatment VAS will be consecutively measured every 15 minutes until 1 hour after treatment.
Minimal and maximal VAS score of every measurement is 0 to 100 millimeters.
VAS scores at 1 hour after treatment were the primary outcome measurement.
The patients who had <50% decrement between pre- and 1-hour post-treatment VAS or post-treatment scores > 40 millimeters were defined as "Non-responders"(worse outcome).
In the same way, those who had ≥ 50% decrement between pre- and 1-hour post-treatment VAS and post-treatment scores≤ 40 millimeters were defined as "Responders" (good outcome).
|
1 hour after treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants in the Predefined "Responders"
Time Frame: pretreatment and 1 hour after treatment
|
"Responders" define the participants who have ≥ 50% decrease in post-treatment pain scores compared with the pre-treatment evaluation and also have the post-treatment scores ≤ 40 at the end of the study.
|
pretreatment and 1 hour after treatment
|
|
Number of Participants in the Predefined "Non-responders"
Time Frame: pretreatment and 1 hour after treatment
|
"Non-responders" defined the participants who had < 50% decrease in post-treatment VAS compared with pre-treatment evaluation or post-treatment scores > 40 at the end of the study.
|
pretreatment and 1 hour after treatment
|
|
Number of Participants With Adverse Effect
Time Frame: 1 hour after treatment
|
The adverse effects include blurred vision, dry mouth, dizziness, headache, palpitation and diarrhea.
|
1 hour after treatment
|
|
Number of Participants That Have Overall Satisfaction on the Treatment
Time Frame: 1 hour after treatment
|
The satisfaction will be assessed by a simple, self-reported yes/no question.
|
1 hour after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Khrongwong Musikatavorn, MD, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Signs and Symptoms, Digestive
- Emergencies
- Dyspepsia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Enzyme Inhibitors
- Antiemetics
- Gastrointestinal Agents
- Adjuvants, Anesthesia
- Proton Pump Inhibitors
- Mydriatics
- Scopolamine
- Antacids
- Pantoprazole
- Butylscopolammonium Bromide
- Anti-Ulcer Agents
Other Study ID Numbers
Other Study ID Numbers
- 619/2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.